Harry Moultrie

ORCID: 0000-0001-9722-0699
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HIV/AIDS Research and Interventions
  • COVID-19 epidemiological studies
  • SARS-CoV-2 and COVID-19 Research
  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment
  • Tuberculosis Research and Epidemiology
  • Vaccine Coverage and Hesitancy
  • COVID-19 Clinical Research Studies
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Poverty, Education, and Child Welfare
  • HIV/AIDS Impact and Responses
  • COVID-19 and healthcare impacts
  • HIV-related health complications and treatments
  • Adolescent Sexual and Reproductive Health
  • COVID-19 Pandemic Impacts
  • Viral Infections and Outbreaks Research
  • Pneumonia and Respiratory Infections
  • Infectious Diseases and Tuberculosis
  • COVID-19 diagnosis using AI
  • Global Maternal and Child Health
  • Global Health Workforce Issues
  • Diagnosis and treatment of tuberculosis
  • SARS-CoV-2 detection and testing
  • Healthcare Policy and Management
  • Orthopedic Infections and Treatments

National Health Laboratory Service
2014-2025

National Institute for Communicable Diseases
2020-2025

University of the Witwatersrand
2013-2023

University of Cape Town
2009-2022

Boston University
2022

Africa University
2022

Stellenbosch University
2022

National Center for Communicable Diseases
2022

Respiratory and Meningeal Pathogens Research Unit
2016

Chris Hani Baragwanath Hospital
2009-2015

We provide two methods for monitoring reinfection trends in routine surveillance data to identify signatures of changes risk and apply these approaches from South Africa's severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic date. Although we found no evidence increased associated with circulation the Beta (B.1.351) or Delta (B.1.617.2) variants, did find clear, population-level suggest immune evasion by Omicron (B.1.1.529) variant previously infected individuals Africa....

10.1126/science.abn4947 article EN Science 2022-03-15

Summary Introduction Globally, there have been more than 404 million cases of SARS-CoV-2, with 5.8 confirmed deaths, as February 2022. South Africa has experienced four waves SARS-CoV-2 transmission, the second, third, and fourth being driven by Beta, Delta, Omicron variants, respectively. A key question emergence new variants is extent to which they are able reinfect those who had a prior natural infection. Rationale We developed two approaches monitor routine epidemiological surveillance...

10.1101/2021.11.11.21266068 preprint EN cc-by medRxiv (Cold Spring Harbor Laboratory) 2021-11-11

ABSTRACT Background The SARS-CoV-2 Omicron variant of concern (VOC) almost completely replaced other variants in South Africa during November 2021, and was associated with a rapid increase COVID-19 cases. We aimed to assess clinical severity individuals infected Omicron, using S Gene Target Failure (SGTF) on the Thermo Fisher Scientific TaqPath PCR test as proxy. Methods performed data linkages for (i) laboratory tests, (ii) case data, (iii) genome (iv) DATCOV national hospital surveillance...

10.1101/2021.12.21.21268116 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2021-12-21

Abstract Omicron lineages BA.4 and BA.5 drove a fifth wave of COVID-19 cases in South Africa. Here, we use the presence/absence S-gene target as proxy for SARS-CoV-2 variant/lineage infections diagnosed using TaqPath PCR assay between 1 October 2021 26 April 2022. We link national individual-level data including case, laboratory test hospitalisation data. assess severity multivariable logistic regression comparing risk severe disease, once hospitalised, Delta, BA.1, BA.2 BA.4/BA.5...

10.1038/s41467-022-33614-0 article EN cc-by Nature Communications 2022-10-04

We aimed to assess the effectiveness of a single dose Ad26.COV2.S vaccine (Johnson & Johnson) in health-care workers South Africa during two waves African COVID-19 epidemic.

10.1016/s0140-6736(22)00007-1 article EN cc-by The Lancet 2022-03-01

Nevirapine-based antiretroviral therapy is the predominant (and often only) regimen available for children in resource-limited settings. Nevirapine resistance after exposure to drug prevention of maternal-to-child human immunodeficiency virus (HIV) transmission common, a problem that has led recommendation ritonavir-boosted lopinavir such Regardless whether there been prior nevirapine, performance nevirapine versus young not rigorously established.

10.1056/nejmoa1113249 article EN New England Journal of Medicine 2012-06-21

Background: The prevention of mother-to-child transmission (PMTCT) HIV has been focused mainly on women who are positive at their first antenatal visit, but there is uncertainty regarding the contribution to overall from mothers seroconvert after visit and before weaning. Method: A mathematical model was developed simulate changes in over time, South Africa. allows for infant feeding practices as infants age, temporal provision antiretroviral prophylaxis counseling feeding, well maternal...

10.1097/qai.0b013e3182432f27 article EN JAIDS Journal of Acquired Immune Deficiency Syndromes 2011-12-22

With expanding pediatric antiretroviral therapy (ART) access, children will begin to experience treatment failure and require second-line therapy. We evaluated the probability determinants of virologic switching in South Africa.

10.1097/qai.0b013e3182060610 article EN JAIDS Journal of Acquired Immune Deficiency Syndromes 2010-11-25

Economic and behavioural factors lead to poor outcomes in patients with tuberculosis. We investigated the effects of a package interventions consisting pre-test post-test tuberculosis counselling conditional cash transfers on patient adults undergoing investigation for pulmonary This pragmatic, open-label, individual randomised controlled trial was done nine clinics Johannesburg, South Africa. Participants (aged ≥18 years) were randomly assigned (1:1) intervention group or control (standard...

10.1016/s1473-3099(24)00816-8 article EN cc-by-nc-nd The Lancet Infectious Diseases 2025-02-01

Many HIV-infected children in Southern Africa have been started on antiretroviral therapy (ART), but loss to follow up (LTFU) can be substantial. We analyzed mortality retained care and all starting ART, taking LTFU into account.Children who ART before the age of 16 years 10 programs South Africa, Malawi, Mozambique, Zimbabwe were included. Risk factors for death first year identified Weibull models. A meta-analytic approach was used estimate cumulative at 1 year.Eight thousand two hundred...

10.1097/qai.0b013e3181e0c4cf article EN JAIDS Journal of Acquired Immune Deficiency Syndromes 2010-06-29

Abstract A new SARS-CoV-2 variant of concern, Omicron (B.1.1.529), has been identified based on genomic sequencing and epidemiological data in South Africa. Presumptive cases Africa have grown extremely rapidly, despite high prior exposure moderate vaccination coverage. The available evidence suggests that spread is at least part due to evasion this immune protection, though may also exhibit higher intrinsic transmissibility. Using detailed laboratory from Africa, we estimate the constraints...

10.1101/2021.12.19.21268038 preprint EN cc-by medRxiv (Cold Spring Harbor Laboratory) 2021-12-21

Abstract Following the results of ENSEMBLE 2 study, which demonstrated improved vaccine efficacy a two-dose regimen Ad26.COV.2 given months apart, we expanded Sisonke study had provided single dose to almost 500 000 health care workers (HCW) in South Africa include booster Ad26.COV.2. enrolled 227 310 HCW from 8 November 17 December 2021. Enrolment commenced before onset Omicron driven fourth wave affording us an opportunity evaluate early VE preventing hospital admissions homologous boost...

10.1101/2021.12.28.21268436 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2021-12-29
Sharon Nachman Naiyu Zheng Edward P. Acosta Hedy Teppler Brenda Homony and 95 more Bobbie Graham T. Fenton Xin Xu Larissa Wenning Stephen A. Spector Lisa M. Frenkel C. Alvero C. Worrell Edward Handelsman Andrew Wiznia Harry Moultrie G. Kindra Margaret Ann Sanders Ruth Williams Jennifer Jensen Mónica Acevedo L. Fabregas Andrea Jurgrau Marc Foca Abigail Higgins Jaime Deville Karin Nielsen‐Saines Michele Carter John Swetnam Joan Wilson Michael Donnelly S. Akleh M. Rigaud Aditya Kaul Naomi J. Patel Ashok Gaur L. J. Utech Evelina Cardoso Airton Mota Moreira Breno Santos Raziya Bobat R. Mngqibisa Marlene Burey Jacobo Abadi Mark E. Rosenberg Katherine Luzuriaga D. Picard Jesica Pagano‐Therrien S. Dittmer H. N. Ndiweni Ankit Patel M. DelRey C. McMullen-Jackson Mary E. Paul Ann J. Melvin Corry Venema-Weiss James R. Lane Christy Beneri D. Ferraro E. Infanzon James McAuley Majid Aziz Maureen F. McNichols Stephen I. Pelton Debra McLaud Diana F. Clarke Steven L. Zeichner Ayşegül Akar Debrah M. Thompson Steven D. Douglas Richard M. Rutstein Carol Ann Vincent Mary E. Vachon Michele Alessandro Cavallo Murli Purswani Gaerolwe Masheto Anthony Ogwu Tebogo J. Kakhu Rolando M. Viani A. Darcey Kimberley Norris Sandra Burchett Catherine Kneut Nancy Karthas D Casey Patricia Emmanuel Jorge Luján‐Zilbermann Sohail Rana Patricia Houston Mulu Mengistab Mobeen H. Rathore Ayesha Mirza Tabetha Lynn Gayton Emily Barr Jennifer Dunn Kristine Hahn Zulma Eysallenne FM Howard Kathryn Graham Marinella Della Negra

Background. IMPAACT P1066 is a phase I/II open-label multicenter trial to evaluate pharmacokinetics, safety, tolerability, and efficacy of multiple raltegravir formulations in human immunodeficiency virus (HIV)–infected youth.

10.1093/cid/cit696 article EN Clinical Infectious Diseases 2013-10-21

Background We were tasked by the South African Department of Health to assess cost implications largest ART programme in world adopting sets guidelines issued World Organization between 2010 and 2016. Methods Using data from large clinics (n = 24,244 patients), projections patients need ART, bottom-up analyses, we constructed a population-level health-state transition model with 6-monthly transitions health states depending on patients' age, CD4 cell count/ percentage, and, for adult...

10.1371/journal.pone.0186557 article EN cc-by PLoS ONE 2017-10-30

Alcohol misuse is a key factor underlying the remarkable vulnerability to HIV infection among men and women in sub-Saharan Africa, especially within urban settings. Its effects, however, vary by type of drinking, population group are modified socio-cultural co-factors. We interviewed random sample 1465 living single-sex hostels 1008 adjacent informal settlements inner-city, Johannesburg, South Africa. Being drunk past week was used as an indicator heavy episodic frequency drinking number...

10.1186/s12889-017-4350-4 article EN cc-by BMC Public Health 2017-07-01

Abstract Background Dexamethasone and remdesivir have the potential to reduce coronavirus disease 2019 (COVID)–related mortality or recovery time, but their cost-effectiveness in countries with limited intensive care resources is unknown. Methods We projected unit (ICU) needs capacity from August 2020 January 2021 using South African National COVID-19 Epi Model. assessed of (1) administration dexamethasone ventilated patients nonventilated patients, (2) alone both (3) only, (4) all relative...

10.1093/ofid/ofab040 article EN cc-by-nc-nd Open Forum Infectious Diseases 2021-01-29
Coming Soon ...